-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the acceleration of new drug review, the normalization of medical insurance negotiation and centralized procurement, and the support of capital and other factors, pharmaceutical companies are enthusiastic about innovation
.
The data shows that as of November 2019, 2020, and 2021, the number of Phase I clinical projects increased by 118, 54, and 172, respectively.
The industry expects that the number of domestic clinical trial projects will continue to grow in the next few years
.
From the perspective of the main focus of new drug research and development at home and abroad, ADC, double antibody, and CAR-T cells are three important directions, and these three domestic new drug research and development fields account for an important proportion of global research and development
.
Among them, ADC projects under research accounted for 36% (144/400), double antibody accounted for 44% (260/588), and CAR-T projects accounted for 37% (260/697)
.
ADC ADC, or antibody-conjugated drug, is an innovative drug composed of antibodies, toxins and linkers, which can precisely deliver toxins to tumor cells to play a killing effect
.
In recent years, the research and development of ADC drugs has been hot, and the market scale has continued to expand.
It is expected that the domestic market scale will reach 21 billion US dollars in 2025, and the compound growth rate from 2020 to 2025 will exceed 50%
.
The considerable ADC drug market is attracting domestic companies to expand their layout.
Among them, Vidicitumab, independently developed by Rongchang Bio, has been approved for marketing in June 2021, becoming an original domestic new drug in the field of ADC drugs
.
In addition, Hengrui Medicine, Zhejiang Medicine, Kelun Botai, Duoxi Bio, Lepu Bio, and Junshi Bio have also built their own ADC technology platforms
.
According to statistics, there are currently hundreds of ADC research projects in China, of which nearly 40 ADC projects have entered the clinical stage.
It is expected that the next 3-5 years will usher in the harvest period, and the track will become more crowded
.
Bispecific antibody is a new type of second-generation antibody with two specific antigen binding sites, which can interact with target cells and functional cells at the same time, thereby enhancing the killing of target cells
.
In recent years, with the rapid increase in the research and development of new macromolecular drugs in China, the double-antibody track has attracted a number of companies to deploy
.
At present, there are more than 200 dual-antibody projects under development in China, about 80 of which are in the clinical stage
.
The data shows that in the first four months of 2021 alone, the number of CDE double-antibody projects accepted reached 29, an increase of about 9 times compared with the same period of the previous year
.
In the domestic double antibody project, including Kangfang Bio, Corning Jereh, Henlius, Hengrui, etc.
have participated in the research and development
.
Entering 2022, good news came one after another in the field of double-antibody R&D
.
For example, on January 5, Pharmaco announced that its self-developed Kadeninumab (AK104) combined with AK112 double antibody phase Ib/II clinical trial application was approved by NMPA, with or without chemotherapy for the treatment of advanced non-small cell lung cancer; On January 6, Henlius' PD-L1/TIGIT dual-antibody HLX301 clinical trial application was accepted by NMPA for the treatment of various advanced solid tumors
.
CAR-T cell therapy CAR-T cell therapy mainly transfers CAR-T cells cultured in vitro into the human body, and activates T cells to attack and kill tumor cells in the patient's body, so it has great potential in cancer treatment
.
In recent years, domestic pharmaceutical companies have been accelerating their deployment in the field of CAR-T cell therapy
.
At present, two CAR-T cell therapy products have been launched in China: Akilance, which was introduced by Fosun Kite, and Ruiki Orenza, which was developed by WuXi Junuo on the basis of JCAR017 of Juno in the United States.
The number of companies is growing, including Fosun Kite, WuXi Junuo, Legend Bio, Keji Bio, Reindeer Medical, Sibiman Bio, Innovent Bio, etc.
There are more than 100 CAR-T projects under development
.
With the opening of the first year of cell therapy in China and the continuous increase in capital, the industry expects that the market size of CAR-T cell therapy will continue to expand in the future
.
Data predicts that the CAR-T cell market will grow at an annual rate of 20.
2% and will be worth $20.
3 billion by 2027
.
.
The data shows that as of November 2019, 2020, and 2021, the number of Phase I clinical projects increased by 118, 54, and 172, respectively.
The industry expects that the number of domestic clinical trial projects will continue to grow in the next few years
.
From the perspective of the main focus of new drug research and development at home and abroad, ADC, double antibody, and CAR-T cells are three important directions, and these three domestic new drug research and development fields account for an important proportion of global research and development
.
Among them, ADC projects under research accounted for 36% (144/400), double antibody accounted for 44% (260/588), and CAR-T projects accounted for 37% (260/697)
.
ADC ADC, or antibody-conjugated drug, is an innovative drug composed of antibodies, toxins and linkers, which can precisely deliver toxins to tumor cells to play a killing effect
.
In recent years, the research and development of ADC drugs has been hot, and the market scale has continued to expand.
It is expected that the domestic market scale will reach 21 billion US dollars in 2025, and the compound growth rate from 2020 to 2025 will exceed 50%
.
The considerable ADC drug market is attracting domestic companies to expand their layout.
Among them, Vidicitumab, independently developed by Rongchang Bio, has been approved for marketing in June 2021, becoming an original domestic new drug in the field of ADC drugs
.
In addition, Hengrui Medicine, Zhejiang Medicine, Kelun Botai, Duoxi Bio, Lepu Bio, and Junshi Bio have also built their own ADC technology platforms
.
According to statistics, there are currently hundreds of ADC research projects in China, of which nearly 40 ADC projects have entered the clinical stage.
It is expected that the next 3-5 years will usher in the harvest period, and the track will become more crowded
.
Bispecific antibody is a new type of second-generation antibody with two specific antigen binding sites, which can interact with target cells and functional cells at the same time, thereby enhancing the killing of target cells
.
In recent years, with the rapid increase in the research and development of new macromolecular drugs in China, the double-antibody track has attracted a number of companies to deploy
.
At present, there are more than 200 dual-antibody projects under development in China, about 80 of which are in the clinical stage
.
The data shows that in the first four months of 2021 alone, the number of CDE double-antibody projects accepted reached 29, an increase of about 9 times compared with the same period of the previous year
.
In the domestic double antibody project, including Kangfang Bio, Corning Jereh, Henlius, Hengrui, etc.
have participated in the research and development
.
Entering 2022, good news came one after another in the field of double-antibody R&D
.
For example, on January 5, Pharmaco announced that its self-developed Kadeninumab (AK104) combined with AK112 double antibody phase Ib/II clinical trial application was approved by NMPA, with or without chemotherapy for the treatment of advanced non-small cell lung cancer; On January 6, Henlius' PD-L1/TIGIT dual-antibody HLX301 clinical trial application was accepted by NMPA for the treatment of various advanced solid tumors
.
CAR-T cell therapy CAR-T cell therapy mainly transfers CAR-T cells cultured in vitro into the human body, and activates T cells to attack and kill tumor cells in the patient's body, so it has great potential in cancer treatment
.
In recent years, domestic pharmaceutical companies have been accelerating their deployment in the field of CAR-T cell therapy
.
At present, two CAR-T cell therapy products have been launched in China: Akilance, which was introduced by Fosun Kite, and Ruiki Orenza, which was developed by WuXi Junuo on the basis of JCAR017 of Juno in the United States.
The number of companies is growing, including Fosun Kite, WuXi Junuo, Legend Bio, Keji Bio, Reindeer Medical, Sibiman Bio, Innovent Bio, etc.
There are more than 100 CAR-T projects under development
.
With the opening of the first year of cell therapy in China and the continuous increase in capital, the industry expects that the market size of CAR-T cell therapy will continue to expand in the future
.
Data predicts that the CAR-T cell market will grow at an annual rate of 20.
2% and will be worth $20.
3 billion by 2027
.
